Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 1159

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA

Dr Weber speaks with ecancer at ESMO 2017 about the results of a trial in which patients with stage IIIb/c/IV melanoma, identified as high risk individuals, were treated with either nivolumab or ipilimumab.

He describes how, at an interim analysis, the trial was brought to an early close due to the significant benefits in relapse free survival for patients receiving nivolumab compared to ipilimumab, which may indicate the suitability of PD-1 therapy for approval in this indication.

Dr Weber goes on to discuss the utility of CTLA-4 targeted therapies in other skin cancer indications, as well as other diseases, and how it may play important roles in combination therapies, relapsed patients and as an immune primer, noting that while it is not for everyone, it remains a key part of the anti-cancer armamentarium.

Read more about these results here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence